7710 Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Health Statistics, 

Meeting of the ICD–10 Coordination 

and Maintenance Committee 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), National 

Center for Health Statistics (NCHS), 

Classifications and Public Health Data 

Standards Staff, announces the 

following meeting of the ICD–10 

Coordination and Maintenance (C&M) 

Committee. This meeting is open to the 

public, limited only by the number of 

audio lines available. Online 

registration is required. 

DATES: The meeting will be held on 

March 19, 2024, from 9 a.m. to 5 p.m., 

EDT, and March 20, 2024, from 9 a.m. 

to 5 p.m., EDT. 

ADDRESSES: This is a virtual meeting. 

Register in advance at https://

cms.zoomgov.com/webinar/register/ 

WN_zqbhSXNtSEmAVWJhs4-4kA. The 

Webinar ID is 161 010 6901; the 

Passcode is 681647. After registering, 

you will receive a confirmation email 

containing information about joining the 

meeting. Further information will be 

provided on each of the respective web 

pages when it becomes available. For 

CDC, NCHS: https://www.cdc.gov/nchs/ 

icd/icd10cm_maintenance.htm. For the 

Centers for Medicare & Medicaid 

Services, Department of Health and 

Human Services: https://www.cms.gov/ 

medicare/coding-billing/icd-10-codes/ 

icd-10-coordination-maintenancecommittee-materials. 

FOR FURTHER INFORMATION CONTACT: 

Traci Ramirez, Medical Classification 

Specialist, National Center for Health 

Statistics, Centers for Disease Control 

and Prevention, 3311 Toledo Road, 

Hyattsville, Maryland 20782–2064. 

Telephone: (301) 458–4454; Email: 

TRamirez@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The ICD–10 Coordination 

and Maintenance (C&M) Committee is a 

public forum for the presentation of 

proposed modifications to the 

International Classification of Diseases, 

Tenth Revision, Clinical Modification 

(CM) and ICD–10 Procedure Coding 

System (PCS). 

Matters to be Considered: The 

tentative agenda will include 

discussions on the ICD–10–CM and 

ICD–10–PCS topics listed below. 

Agenda items are subject to change as 

priorities dictate. Please refer to the 

posted agenda for updates one month 

prior to the meeting. 

ICD–10–PCS Topics: 

1. Restriction Using Thoracoabdominal 

Branch Endoprosthesis * 

2. Tibiotalocalcaneal Fusion with 

Fixation Implant * 

3. Fiber Optic 3D Real-time Device 

Guidance ** 

4. Visualization and Analysis of Brain 

Networks in Magnetic Resonance 

Imaging * 

5. Lymphatic Bypass 

6. Performance of Circulatory Filtration 

7. Quantitative Antimicrobial 

Susceptibility Testing of Blood 

Cultures 

8. Transcatheter Tricuspid Valve 

Replacement * 

9. Cellular Assessment via Microfluidic 

Deformability Cytometry ** 

10. Fixation of Lumbar Facet Joint 

11. Extracorporeal Blood Pathogen 

Removal ** 

12. Application of prademagene 

zamikeracel ** 

13. Adoptive Immune Therapy 

14. Administration of dasiglucagon 

15. Drug-eluting Resorbable Scaffold 

System 

16. Continuous Monitoring and 

Assessment of Vascular Blood 

Flow * 

17. Paclitaxel-coated Balloon Catheter 

for Percutaneous Coronary 

Intervention 

18. Division of Bioprosthetic Aortic 

Valve Leaflets ** 

19. Computer-aided Triage and 

Notification for Measurement of 

Intracranial Cerebrospinal Fluid 

Flow * 

20. Implantation of Bioengineered 

Vessel ** 

21. Rapid Antimicrobial Susceptibility 

Testing of Blood Cultures * 

22. Stereoelectroencephalographic 

Radiofrequency Ablation of Brain 

and Nervous Tissue 

23. Insertion of Antibiotic Instilling 

Joint Spacer ** 

24. Posterior Fixation of the 

Thoracolumbar Spine * 

25. Section X Updates 

26. Addenda and Key Updates 

27. Administration of bentracimab ** 

28. Administration of cefepimetaniborbactam * 

29. Administration of ceftobiprole 

medocaril * 

30. Administration of obecabtagene 

autoleucel ** 

31. Administration of odronextamab * 

32. Administration of Orca-T ** 

33. Administration of RP–L201 

(marnetegragene autotemcel) * 

34. Administration of zanidatamab ** 

35. Donislecel-jujn Allogeneic 

Pancreatic Islet Cellular Suspension 

for Hepatic Portal Vein Infusion * 

* Requestor has submitted a new 

technology add-on payment (NTAP) 

application for FY 2025 consideration. 

** Request is for an October 1, 2024, 

implementation date, and the requestor 

intends to submit an NTAP application 

for FY 2026 consideration. 

Presentations for procedure code 

requests are conducted by both the 

requestor and the Centers for Medicare 

& Medicaid Services (CMS) during the 

C&M Committee meeting. Discussion 

from the requestor generally focuses on 

the clinical issues for the procedure or 

technology, followed by the proposed 

coding options from a CMS analyst. 

Topics presented may also include 

requests for new procedure codes that 

relate to a new technology add-on 

payment (NTAP) policy request. 

CMS has modified the approach for 

presenting the new NTAP-related ICD– 

10–PCS procedure code requests that 

involve the administration of a 

therapeutic agent. For the March 19–20, 

2024, ICD–10 C&M Committee meeting, 

consistent with the requirements of 

section 1886(d)(5)(K)(iii) of the Social 

Security Act, applicants submitted 

requests to create a unique procedure 

code to describe the administration of a 

therapeutic agent, such as the option to 

create a new code in Section X within 

the ICD–10–PCS procedure code 

classification. CMS will initially display 

only those meeting materials associated 

with the NTAP-related ICD–10–PCS 

procedure code requests that involve the 

administration of a therapeutic agent on 

the CMS website in early March 2024 at: 

https://www.cms.gov/medicare/codingbilling/icd-10-codes/icd-10- 

coordination-maintenance-committeematerials. 

The nine NTAP-related ICD–10–PCS 

procedure code requests that involve the 

administration of a therapeutic agent 

are: 

1. Administration of bentracimab ** 

2. Administration of cefepimetaniborbactam * 

3. Administration of ceftobiprole 

medocaril * 

4. Administration of obecabtagene 

autoleucel ** 

5. Administration of odronextamab * 

6. Administration of Orca-T ** 

7. Administration of RP–L201 

(marnetegragene autotemcel) * 

8. Administration of zanidatamab ** 

9. Donislecel-jujn Allogeneic Pancreatic 

Islet Cellular Suspension for 

Hepatic Portal Vein Infusion * 

* Requestor has submitted an NTAP 

application for FY 2025 consideration. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices 7711 

** Request is for an October 1, 2024, 

implementation date, and the requestor 

intends to submit an NTAP application 

for FY 2026 consideration. 

These topics will not be presented 

during the March 19–20, 2024, meeting. 

CMS will solicit public comments 

regarding any clinical questions or 

coding options included for these 

procedure code topics in advance of the 

meeting continuing through the end of 

the respective public comment periods. 

Members of the public should send any 

questions or comments to the CMS 

mailbox at: ICDProcedureCodeRequest@

cms.hhs.gov. 

CMS intends to post a question-andanswer document in advance of the 

meeting to address any clinical or 

coding questions that members of the 

public may have submitted. Following 

the conclusion of the meeting, CMS will 

post an updated question-and-answer 

document to address any additional 

clinical or coding questions that 

members of the public may have 

submitted during the meeting that CMS 

was not able to address or that were 

submitted after the meeting. 

The NTAP-related ICD–10–PCS 

procedure code requests that do not 

involve the administration of a 

therapeutic agent and all non-NTAPrelated procedure code requests will 

continue to be presented during the 

virtual meeting on March 19, 2024, 

consistent with the standard meeting 

process. 

CMS will make all meeting materials 

and related documents available at: 

https://www.cms.gov/medicare/codingbilling/icd-10-codes/icd-10- 

coordination-maintenance-committeematerials. Any inquiries related to the 

procedure code topics scheduled for the 

March 19, 2024, ICD–10 C&M 

Committee meeting day that are under 

consideration for October 1, 2024, 

implementation should be sent to the 

CMS mailbox at: 

ICDProcedureCodeRequest@

cms.hhs.gov. 

ICD–10–CM Topics: 

1. Abnormal Anti-cyclic Citrullinated 

Peptide Antibody and/or 

Rheumatoid Factor Without Current 

or Prior Clinical Diagnosis of 

Rheumatoid Arthritis 

2. APOL1-mediated Kidney Disease 

3. Baked Egg Tolerance 

4. Baked Milk Tolerance 

5. Coding of Firearms Injuries Default 

6. DLG4-related Synaptopathy 

7. Flank Anatomical Specificity 

8. Glutamate Receptor, Ionotropic, 

Gene-related Neurodevelopmental 

Disorders 

9. Gulf War Illness 

10. Hyperoxaluria 

11. Post-exertional Malaise 

12. SCN2A-related Disorders 

13. SLC6A1-related Disorders 

14. STXBP1-related Disorders 

15. Usher Syndrome 

16. Addenda 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–02178 Filed 2–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–24–1402] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Surveillance of 

HIV-related service barriers among 

Individuals with Early or Late HIV 

Diagnoses (SHIELD)’’ to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on October 

06, 2023, to obtain comments from the 

public and affected agencies. CDC 

received two comments to the previous 

notice. This notice serves to allow an 

additional 30 days for public and 

affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Surveillance of HIV-related service 

barriers among Individuals with Early or 

Late HIV Diagnoses (SHIELD) (OMB 

Control No. 0920–1402, Exp. 05/31/ 

2026)—Revision—National Center for 

HIV, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

National HIV Surveillance System 

(NHSS) data indicate that 36,940 

adolescents and adults received an HIV 

diagnosis in the United States and 

dependent areas in 2019. During 2015– 

2019, the overall rate of annual 

diagnoses decreased only slightly, from 

12.4 to 11.1 per 100,000 persons. 

Although not every jurisdiction reports 

complete laboratory data needed to 

identify the stage of infection, data from 

the majority of jurisdictions show that 

many of these cases were classified as 

Stage 0 (6.9%) or Stage 3 (21.5%) 

infection (i.e., cases diagnosed in early 

infection or late infection, respectively). 

Early and late diagnoses represent 

recent failures in prevention and testing 

systems, and opportunities to 


lotter on DSK11XQN23PROD with NOTICES1